Skip to main content
Premium Trial:

Request an Annual Quote


BioVeris announced this week that it has launched eight new products for use in life science research to measure potential immune response to protein-based therapeutics that are in development.
According to the company, two of the products are pharmacodynamic biomarkers, which detect human IL-2 and TNF-alpha and measure cytokine levels that may be elevated due to a drug treatment response.
The other six products can be used for immunogenicity testing, assay development, and hybridoma screening. “The products are composed of a panel of antibodies that are prelabeled with BioVeris’ detection label BV-TAG Plus and may be used to quantitate and characterize the following mouse antibodies: IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3,” the company said in a statement.

Filed under

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.